Taxon Therapeutics
Recombinant Therapeutic Proteins for Rare Autoimmune Diseases
Company Overview
Snapshot
Founded in June 2020 by David Cogen and Dobroslav Melamed, Taxon Therapeutics operated with 1–10 employees. The company focused on developing recombinant therapeutic proteins for rare autoimmune diseases. In April 2024, Taxon Therapeutics ceased operations.
Business overview
Taxon Therapeutics is a biopharmaceutical company specializing in the development and commercialization of recombinant therapeutic proteins. The company's core product, TAX-01, is designed to treat autoimmune hemolytic anemia, a severe and rare blood disorder. Taxon Therapeutics operates within the Health Tech & Life Sciences sector, specifically targeting the pharmaceutical and drug development industries for rare diseases.
Strategic signal
In October 2020, Taxon Therapeutics entered into a preliminary agreement with Mabion regarding MabionCD20. This collaboration indicated early strategic alignment and potential for product development in the biopharmaceutical space, signaling the company's initial efforts to advance its therapeutic pipeline through partnerships.
Company Intelligence Q&A
- What is Taxon Therapeutics' primary focus?
- Taxon Therapeutics focuses on the development and commercialization of recombinant therapeutic proteins for rare autoimmune diseases with unmet medical needs.
- What is the status of Taxon Therapeutics?
- Taxon Therapeutics ceased operations in April 2024.
- Who are the founders of Taxon Therapeutics?
- Taxon Therapeutics was co-founded by David Cogen, who served as CEO, and Dobroslav Melamed, who served as VP Business Development.
- What is TAX-01?
- TAX-01 is Taxon Therapeutics' product designed for the treatment of adults with autoimmune hemolytic anemia, a severe and rare blood disorder.
- Did Taxon Therapeutics engage in any strategic partnerships?
- In October 2020, Taxon Therapeutics had a preliminary agreement with Mabion concerning MabionCD20.